Gautschi Oliver P, Frey Sönke P, Zellweger René
Department of Orthopaedic and Trauma Surgery, Royal Perth Hospital, School of Anatomy and Human Biology, University of Western Australia, Perth, Western Australia, Australia.
ANZ J Surg. 2007 Aug;77(8):626-31. doi: 10.1111/j.1445-2197.2007.04175.x.
The role of bone morphogenetic proteins (BMPs) in bone healing has been shown in numerous animal models. To date, at least 20 BMPs have been identified, some of which have been shown in vitro to stimulate the process of stem cell differentiation into osteoblasts in human and animal models. Having realized the osteoinductive properties of BMPs and having identified their genetic sequences, recombinant gene technology has been used to produce BMPs for clinical application - most commonly, as alternatives or adjuncts in the treatment of cases in which fracture healing is compromised. BMP-2 and BMP-7 are approved for clinical use in open fractures of long bones, non-unions and spinal fusion. However, despite significant evidence of their potential benefit to bone repair and regeneration in animal and preclinical studies, there is, to date, a dearth of convincing clinical trials. The purpose of this paper is to give a brief overview of BMPs and to critically review the clinical data currently available on the use of BMP-2 and BMP-7 in fracture healing.
骨形态发生蛋白（BMPs）在骨愈合中的作用已在众多动物模型中得到证实。迄今为止，已鉴定出至少20种BMPs，其中一些在体外已被证明可在人和动物模型中刺激干细胞分化为成骨细胞的过程。在认识到BMPs的骨诱导特性并确定其基因序列后，重组基因技术已被用于生产用于临床应用的BMPs——最常见的是，作为骨折愈合受损病例治疗中的替代方法或辅助手段。BMP-2和BMP-7已被批准用于长骨开放性骨折、骨不连和脊柱融合的临床治疗。然而，尽管在动物和临床前研究中有大量证据表明它们对骨修复和再生有潜在益处，但迄今为止，缺乏令人信服的临床试验。本文的目的是简要概述BMPs，并严格审查目前关于BMP-2和BMP-7在骨折愈合中应用的临床数据。
